A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease-Reference-Cited by-同舟云学术

A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease

Published:2023-10 Issue:4 Volume:79 Page:888-897
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Romero-Gómez Manuel,Lawitz Eric,Shankar R. Ravi^ORCID,Chaudhri Eirum,Liu Jie,Lam Raymond L.H.,Kaufman Keith D.^ORCID,Engel Samuel S.^ORCID,Bruzone Santiago Oscar,Coronel Maria Jimena,Gruz Fernando M.,MacKinnon Ignacio,George Jacob,Muller Kate,Lee Samuel S.,Caussy Cyrielle,Petit Jean Michel,Ari Ziv Ben,Braun Marius,Katchman Helena,Lurie Yoav,Veitsman Ella,Zuckerman Eli,Aghemo Alessio,Basili Stenfania,Fracanzani Anna Ludovica,Pietrangelo Antonello,Sacerdoti David,Rubio Arce Jose Francisco,de Guevara Cetina Alma Laura Ladron,Chavez-Tapia Norberto Carlos,Reyes Eira Cerda,Pinzon Te Lourdes Lol-Be,Baker John R.,Ngu Jeffrey,Orr David,Janczewska Ewa,Matusik Pawel,Stanislaw Sadurski Maciej Murawski,Akinina Anna Valerievna,Alpenidze Diana Nodarievna,Bogomolov Pavel,Ermakova Polina Yurievna,Golovach Albina V.,Kim Sang Gyune,Lee Jin-Woo,Paik Yong Han,Park Jun Yong,Yeon Jong Eun,Blasco Victor Vargas,Madueno Francisco Jose Tinahones,Panero Jose Luis Calleja,Perez Esther Molina,Romero-Gómez Manuel,Cheng Pin-Nan,Jeng Wen-Juei,Liu Chun-Jen,Akyuz Filiz,Balaban Hatice Yasemin,Basaranoglu Metin,Demir Tevfik,Idilman Ramazan,Karakan Tarkan,Gyrina Olga,Kolesnikova Olena Vadimivna,Pyvovar Sergiy M.,Oliinyk Oleksandr,Skrypnyk Igor,Bassan Isaac,Bowman William Kelly,Denham Douglas Scott,Ghalib Reem,Lawitz Eric J.,Lucas Kathryn Jean,Mohseni Rizwana H.,Sanchez William Eduardo,Vierling John Moore

Funder

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Hepatology

Reference27 articles.

1. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review;Younossi;Hepatology,2023

2. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease;Kechagias;Metabolism,2020

3. Nonalcoholic steatohepatitis: a review;Sheka;JAMA,2020

4. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications;Fabbrini;Hepatology,2010

5. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes;Godoy-Matos;Diabetology Metab Syndr,2020

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes;Expert Opinion on Drug Metabolism & Toxicology;2024-09-13

2. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article;Indian Journal of Endocrinology and Metabolism;2024-09-04

3. Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease: a review;Frontiers in Pharmacology;2024-09-03

4. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

5. Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease;World Journal of Gastroenterology;2024-08-14